Mepolizumab

Red

Brand Name(s):Nucala

Indication:Asthma

Rationale:1,2

Considered:Jan-16

Review Date:Feb-26

Comments:
NICE TA671 Mepolizumab, as an add-on therapy, is recommended as an option for severe refractory eosinophilic asthma in adults who have agreed to and followed an optimised standard treatment plan, under certain set clinical criteria. This guidance updates and replaces NICE TA guidance 431.

NICE TA431
Mepolizumab for treating severe refractory eosinophilic asthma
Jan-17